Enlivex Ltd.
ENLV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001596812
No open-market purchases or sales by Enlivex Ltd. insiders were filed in the last 90 days; 25 institutions reported holding it in 13F filings for Q2 2026, worth $2.34M in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −9 vs. previous quarter
- 25
- 13F valueReported value at the end of Q2 2026
- $2.34M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding ENLV, Q2 2026
1 superinvestor reports holding Enlivex Ltd. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Enlivex Ltd. insiders from Form 4, newest first.
No open-market purchases or sales by Enlivex Ltd. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Enlivex Ltd. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ARK Investment Management LLCSuperinvestorARK Invest | 2,382,731 | $1.31M | 0.01% | +1,754,421+279.2% | Added |
| Prelude Capital Management, LLC | 321,306 | $176.7K | 0.01% | +95,568+42.3% | Added |
| Bank of America Corp | 193,150 | $106.0K | 0.00% | +62,749+48.1% | Added |
| Two Sigma Investments, LP | 183,924 | $101.1K | 0.00% | +37,512+25.6% | Added |
| Susquehanna International Group, LLP | 157,648 | $86.7K | 0.00% | +147,334+1,428.5% | Added |
| Persistent Asset Partners Ltd | 147,879 | $81.3K | 0.03% | +147,879 | New |
| Renaissance Technologies LLC | 133,900 | $73.6K | 0.00% | +5,708+4.5% | Added |
| Geode Capital Management, LLC | 129,858 | $71.4K | 0.00% | +49,298+61.2% | Added |
| JPMorgan Chase & Co | 121,296 | $70.4K | 0.00% | −4,652−3.7% | Reduced |
| Simplex Trading, LLC | 111,406 | $61.3K | 0.00% | +108,791+4,160.3% | Added |